| editorial | Q871232 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/JAMA.1997.03540390068038 |
| P698 | PubMed publication ID | 9103350 |
| P2093 | author name string | D Rennie | |
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1238-1243 | |
| P577 | publication date | 1997-04-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Thyroid storm | |
| P478 | volume | 277 |
| Q36918720 | A comparison of conflict of interest policies at peer-reviewed journals in different scientific disciplines. |
| Q42764015 | Accepting commercial sponsorship. Disclosure helps--but is not a panacea |
| Q30670681 | Accessing third-party data for research: trust me? Trust me not? |
| Q24186775 | Adhesion prevention agents for gynaecological surgery: an overview of Cochrane reviews |
| Q33811024 | Alteplase for stroke. Uncertainty remains about efficacy |
| Q33579214 | Applied pharmacoeconomics. When can publication be legitimately withheld? |
| Q33998375 | Association of Professors of Medicine. Ethical issues in clinical research: an issue for all internists |
| Q24544212 | Attacks on science: the risks to evidence-based policy |
| Q24793279 | Balancing commercial and public interests |
| Q60517540 | Concerned Journals, Editors And ICMJE |
| Q34223423 | Confidentiality: consent is not sufficient |
| Q43187440 | Conflict of interest in biomedical publications |
| Q41767716 | Conflict, what conflict? |
| Q53389989 | Conflicts of interest and AJRCCM: restating policy and a new form to upload. |
| Q34918959 | Conflicts of interest in drug development: the practices of Merck & Co., Inc. |
| Q24644642 | Conflicts of interest, authorship, and disclosures in industry-related scientific publications: the tort bar and editorial oversight of medical journals |
| Q42762320 | Direct to consumer advertising of prescription drugs. An idea whose time should not come |
| Q53592816 | Disclosing conflicts of interest |
| Q30226736 | Disease mongering and the fear of pandemic influenza |
| Q34011069 | Early Toronto experience with new standards for industry-sponsored clinical research: a progress report |
| Q34335952 | Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans |
| Q34223415 | Efforts to ban direct-to-consumer advertising in New Zealand: a call to action |
| Q45983750 | Ethical issues in industry-sponsored research. |
| Q30350217 | Evidence-based ethics for neurology and psychiatry research. |
| Q28755551 | Finer nuances of clinical study agreements for research trials |
| Q89002563 | Freedom of Science - Can Industry Influence What Scientists Publish? |
| Q34223408 | How to change clinical behaviour: no answers yet. |
| Q33815155 | How to dance with porcupines: rules and guidelines on doctors' relations with drug companies |
| Q36484339 | Industry Support of Medical Research: Important Opportunity or Treacherous Pitfall? |
| Q35372675 | Industry and evidence-based medicine: Believable or conflicted? A systematic review of the surgical literature |
| Q73850662 | Industry-sponsored research in minimally invasive surgery |
| Q36088088 | Institutional conflicts of interest: protecting human subjects, scientific integrity, and institutional accountability |
| Q35559637 | Institutional ethics review of clinical study agreements |
| Q33874170 | Integrity in scientific publishing |
| Q96954087 | Intractable hiccups as a rare gastrointestinal manifestation in severe endocrine and metabolic crisis: case report and review of the literature |
| Q78109124 | Is there still a role for Academia? |
| Q30578396 | Japan's loss of leadership role in access to drug data |
| Q74588535 | Look, no strings: publishing industry-funded research |
| Q53589322 | MDM policy regarding financial support of authors. |
| Q42773769 | Maintaining the integrity of the scientific record |
| Q34555565 | Marketing, media, wishful thinking, and conflicts of interest: inflating the value of new medical technology |
| Q24797709 | Materializing research promises: opportunities, priorities and conflicts in translational medicine |
| Q24810066 | Medical journals are an extension of the marketing arm of pharmaceutical companies |
| Q34577371 | Neuromarketing and consumer neuroscience: contributions to neurology |
| Q28184622 | Patients' health or company profits? The commercialisation of academic research |
| Q53579137 | Paying the piper for pharmacoeconomic studies. |
| Q40973018 | Perception of Ethical Misconduct by Neuropsychology Professionals in Latin America |
| Q38498583 | Pharmaceutical advertising revenue and physician organizations: how much is too much? |
| Q24673248 | Pharmaceutical industry sponsorship and research outcome and quality: systematic review |
| Q31122209 | Promises and pitfalls of data sharing in qualitative research |
| Q28728749 | Public welfare agenda or corporate research agenda? |
| Q24201257 | Radioiodine therapy versus anti-thyroid medications for Graves' disease |
| Q24186122 | Radioiodine therapy versus antithyroid medications for Graves' disease |
| Q41665587 | Relevance of pharmacokinetics in narrow therapeutic index drugs |
| Q21203744 | Reporting bias in medical research - a narrative review |
| Q64110746 | Reproducible pharmacokinetics |
| Q33701176 | Research ethics in emergency medicine |
| Q41173973 | Research funding, conflicts of interest, and the meta-methodology of public relations |
| Q53434831 | Responsibilities of investigators. |
| Q30885194 | Review of current authorship guidelines and the controversy regarding publication of clinical trial data |
| Q28710019 | SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials |
| Q73814631 | Science and health care: an uneasy partnership |
| Q40818362 | Some observations on current and possible future developments in bioequivalency testing |
| Q24554874 | Sponsorship, authorship and accountability |
| Q53359690 | Sponsorship, authorship, and a tale of two media. |
| Q34377029 | Sponsorship, authorship, and accountability |
| Q74568328 | Sponsorship, authorship, and accountability |
| Q64943138 | Technology Transfer: From the Research Bench to Commercialization: Part 2: The Commercialization Process. |
| Q38836662 | The cardiopulmonary effects and quality of anesthesia after induction with alfaxalone in 2-hydroxypropyl-β-cyclodextrin in dogs and cats: a systematic review |
| Q40837263 | The future of medical journals in the western world |
| Q34992767 | The pharmaceutical industry as an informant |
| Q36886692 | The relationship between the outcome of studies of autologous chondrocyte implantation and the presence of commercial funding |
| Q53583115 | Troubling issues with research publications. |
| Q33815149 | Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement |
| Q30432677 | Women's health, chronic disease, and disease management: new words and old music? |
| Q52929780 | [Declaring conflict of interest in scientific publications. Time for the spotlights and stenographers in the backroom of research financed by the industry?]. |
| Q77166006 | [Sponsorship, authorship and accountability] |
| Q81403418 | [The Cochrane Skin Group] |
Search more.